Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature
- PMID: 25962349
- DOI: 10.1007/s12253-015-9944-5
Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature
Abstract
Breast cancer in very young women under 40 or 35 years attracted a widespread attention. Few studies have focused on women aged below 25 years. The aim of this study was to evaluate the situation of breast cancer in women ≤25 years in the center of Tunisia. Retrospective review from 1993 to 2013. Clinical, histopathological, therapeutic and outcome data were recorded. Cases were classified into different molecular subtypes based on the immunohistochemistry-based definitions. The series included 25 patients. The mean duration of symptoms was 7.5 months. The most common presenting symptom was a palpable mass. Four patients had at least one relative diagnosed with breast cancer. Mammography combined with ultrasound was suggestive of malignancy in 60 % of cases. Curative surgical treatment could be offered in 19 cases. The mean tumor size was 39 mm. Nodal metastases were detected in 9/18 cases. Twenty cases could be classified into: luminal A (5 cases), luminal B (6 cases), Her-2 (1 case), triple negative (6 cases) and unclassified (2 cases). Two women experienced locoregional recurrence and 6 had distant recurrence. Asynchronous contralateral breast cancer occurred in one case. The overall survival at 5 and 10 years was 85 and 75 % respectively. The survival was significantly lower in grade III tumors (p = 0.04) and triple negative tumors (p = 0.03). Breast cancer in women ≤25 years is uncommon. An adequate medical education of young women and physicians is necessary.
Similar articles
-
Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.Tumour Biol. 2016 Jul;37(7):9813-23. doi: 10.1007/s13277-016-4870-z. Epub 2016 Jan 26. Tumour Biol. 2016. PMID: 26810187
-
Primary breast cancer phenotypes associated with propensity for central nervous system metastases.Cancer. 2006 Aug 15;107(4):696-704. doi: 10.1002/cncr.22041. Cancer. 2006. PMID: 16826579
-
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8. Breast Cancer. 2015. PMID: 23749689
-
Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review.Eur J Surg Oncol. 2021 Apr;47(4):796-803. doi: 10.1016/j.ejso.2020.10.008. Epub 2020 Oct 13. Eur J Surg Oncol. 2021. PMID: 33097334 Review.
-
Overview of breast cancer.JAAPA. 2019 Oct;32(10):13-17. doi: 10.1097/01.JAA.0000580524.95733.3d. JAAPA. 2019. PMID: 31513033 Review.
Cited by
-
The circZEB1/miR-337-3p/OGT axis mediates angiogenesis and metastasis via O-GlcNAcylation and up-regulating YBX1 in breast cancer.Heliyon. 2024 Jul 14;10(14):e34079. doi: 10.1016/j.heliyon.2024.e34079. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39114035 Free PMC article.
-
Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients.PLoS One. 2022 Sep 12;17(9):e0269732. doi: 10.1371/journal.pone.0269732. eCollection 2022. PLoS One. 2022. PMID: 36094928 Free PMC article.
-
Breast Cancer in Chinese Females Aged 25 Years and Younger.J Oncol. 2021 Nov 30;2021:4891936. doi: 10.1155/2021/4891936. eCollection 2021. J Oncol. 2021. PMID: 34887923 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous